INSTITUTIONAL RESEARCH

Sudarshan Chemical Industries

Focus remains on balance sheet optimization

We are maintaining REDUCE on Sudarshan Chemical Industries Ltd (SCIL), with a target price of INR 1,028. SCIL has signed two deals recently. The company is acquiring Clariant's Muttenz aluminium dyes facility in one deal while it has signed a definitive agreement to carve out its wholly owned subsidiary VP4 Frankfurt GmbH under the other deal. We see these deals as a disciplined post-Heubach portfolio rationalization which would optimize the balance sheet. The acquisition of aluminium dyes facility from Clariant is a strategic supply-chain integration move — the plant already manufactures Sudarshan's aluminium dyes, and owning it secures long-term supply, preserves specialized know-how, and avoids the operational risk of shifting complex processes to another site. SCIL's divestment in VP4 Frankfurt, GmbH, a non-core intermediate manufacturing subsidiary inherited via the Heubach acquisition, to Celanese Corporation demonstrates the strategy of focusing on rationalization of the portfolio inherited through Heubach by selling the non-core assets and sharpening focus on the strategic pigment business. The divestment is strategically important, especially when viewed in the broader context of Sudarshan's recent actions — the transformational Heubach acquisition, the selective Clariant aluminium dyes plant acquisition, and now the sale of VP4 Frankfurt GmbH. Though the transaction does not seem to be bottom-line accretive, we believe that SCIL's current focus is on potentially creating room for balance sheet deleveraging. We believe that proceeds from selling of VP4 assets will be primarily utilized for debt repayment, given Heubach-related leverage. Key monitorables include the use of sale proceeds, Muttenz plants' revenue and margin profile, interest savings potential, and balance sheet deleveraging. We expect an improvement in net debt to EBITDA from 0.85 in FY27 to 0.20 in FY30. We expect revenue/EBITDA/APAT CAGR of 6/14/40% over FY27-FY30E. The stock is trading at 54.5/27.8/23.4x, basis FY28/29/30E EPS.

Strategic vertical integration: Sudarshan secures aluminium dyes

Sudarshan, through its step-down wholly owned subsidiary Sudarshan Switzerland SLO AG (formerly Heubach Colorants Switzerland AG), has signed a definitive asset sale and transfer agreement with Clariant Additives (Switzerland) AG **(Exhibit 1)**. The company is acquiring an aluminium dyes and chemicals manufacturing facility located in Muttenz, Switzerland for a consideration of CHF 7mn.

Exhibit 1: Key transaction details.

Particulars	Description
Announcement date	25 August 2026
Agreement signed	24 August 2026
Nature of acquisition	Asset acquisition
Seller	Clariant Additives (Switzerland) AG
Base consideration	CHF 7 million or ~INR 0.8bn
Exepcted closing	4 January 2027
Key brands manufactured	Sanodal®, Sanodure®, Sanodye®, Anodal®

Source: Company, HSIE Research

REDUCE

CMP *(as on 25 Sep 2026)*	INR 1,219
Target Price	INR 1,028
NIFTY	23,141

KEY CHANGES	OLD	NEW
Rating	REDUCE	REDUCE
Price Target	INR 911	INR 1,028
EPS %	FY27E	FY28E
	-1.3%	+2.7%

KEY STOCK DATA

Bloomberg code	SCHI IN
No. of Shares (mn)	80
MCap (INR bn) / ($ mn)	97/1,013
6m avg traded value (INR mn)	407
52 Week high / low	INR 1,530/726

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	36.8	54.6	(15.4)
Relative (%)	40.9	56.5	(6.4)

SHAREHOLDING PATTERN (%)

	Mar-26	Jun-26
Promoters	8.19	8.19
FIs & Local MFs	24.90	26.42
FPIs	7.96	8.47
Public & Others	58.95	56.92
Pledged Shares	0.00	0.00

Source: BSE
**Reclassified some promoter and promoter group to public category*

Nilesh Ghuge
nilesh.ghuge@hdfcsec.com
+91-22-6171-7342

Aditya Iyer
aditya.iyer@hdfcsec.com
+91-22-6171-7356

Priya Gupta
priya.gupta1@hdfcsec.com
+91-22-6171-7361

Financial summary

Year Ending March (Rs mn)	1Q FY27	4Q FY26	QoQ (%)	1Q FY26	YoY (%)	FY25	FY26	FY27E	FY28E	FY29E
Net Sales	26,421	27,899	(5.3)	25,069	5.4	33,456	97,872	1,08,782	1,14,652	1,21,472
EBITDA	2,588	2,274	13.8	1,924	34.5	3,810	5,899	6,766	6,995	9,167
APAT	1,034	743	39.1	550	88.0	1,436	486	1,494	1,779	3,485
Diluted EPS (Rs)	13.0	9.4	37.7	7.9	63.7	18.1	6.1	18.8	22.4	43.8
P/E (x)						67.5	199.4	64.9	54.5	27.8
EV/EBITDA(x)						26.9	18.2	15.2	14.7	11.1
RoE (%)						6.3	1.4	4.0	4.3	8.1

Source: Company, HSIE Research

Change in estimates

Y/E Mar	FY27E Old	FY27E New	% Ch	FY28E Old	FY28E New	% Ch
EBITDA (INR mn)	6,838	6,766	(1.0)	7,403	6,995	(5.5)
Adj. EPS (INR/sh)	19.0	18.8	(1.3)	21.8	22.4	2.7

Source: Company, HSIE Research

HSIE vs Consensus estimates

Y/E Mar	FY27E HSIE	FY27E Consensus	% Deviation	FY28E HSIE	FY28E Consensus	% Deviation
EBITDA (INR mn)	6,766	7,747	(12.7)	6,995	10,297	(32.1)
Adj. EPS (INR/sh)	18.8	31.5	(40.3)	22.4	56.0	(60.1)

Source: Bloomberg, HSIE Research

The Muttenz plant has been manufacturing Sudarshan's aluminium dyes for years under an existing supply arrangement. The company already owned the commercial portfolio and customer relationships, while this plant produced the products. As the supply arrangement was coming to an end, Sudarshan decided to purchase this unit given its strategic importance instead of transferring manufacturing elsewhere where it would have to redo the whole process of moving complex multi-step organic chemistry processes, reproducing precise product specifications, customer qualification, technical transfer, etc.

These aluminium dyes are used to color anodized aluminium; a process widely used in sectors such as automotives, consumer electronics, packaging, industrial components, etc. These dyes impart color while preserving the durability and appearance of anodized aluminium. This is a specialized niche within the wider chemicals' universe, rather than a high-volume commodity business. This acquisition is best understood as a supply-security and value-chain integration move, not an expansionary bet like Heubach, which could make it strategically more valuable **(Exhibit 2)** than the CHF 7mn headline consideration suggests. Future financial attractiveness will hinge on plant profitability and Swiss cost structure.

Exhibit 2: Acquisition rationale.

Strategic implications	Description
Long-term supply	Owning the facility provides control over capacity, schedules, availability and long-term planning — materially reducing supply risk.
Difficult to replicate manufacturing capabilities	This site runs complex multi-step organic chemistry, developed across decades in the Sandoz → Clariant → Sudarshan lineage. It brings deep process know-how, experienced operators, established systems and historical manufacturing expertise.
Potential improvement in economics	The company may benefit from removal of supplier margins, better cost control, procurement optimization etc.
Greater control over innovation and development	Complete ownership opens space for new product development, shade and performance improvement, process optimization and portfolio expansion.

Source: Company, HSIE Research

To compare this acquisition with Heubach **(Exhibit 3)**, Heubach acquisition was transformational while in case of Clariant, they are essentially acquiring a manufacturing asset that already produces their products. Integration burden compared to Heubach here should theoretically be much lower because SCIL is not trying to integrate an unfamiliar business. It already knows the products, manufacturing processes, and customers.

Exhibit 3: Heubach vs Clariant Muttenz comparison

Heubach acquisition	Clariant Muttenz acquisition
Large global pigment business	Single specialised manufacturing facility
Added new portfolio, customers & sites	Continues producing existing Sudarshan products
Significant organisational integration	Operational continuity with the same workforce
Cross-country multi-site integration	One site in Switzerland
Transformational	Strategic bolt-on

Source: Company, HSIE Research

Post-Heubach portfolio: Sudarshan monetizes non-core VP4 Frankfurt asset

Sudarshan divested its entire stake in the subsidiary VP4 Frankfurt GmbH to Celanese Corporation for a consideration of EUR 76.5mn or ~INR 8.45bn **(Exhibit 4)**. The agreement was signed on 31 August 2026.


Exhibit 4: Key transaction details.

Particulars	Description
Target sold	VP4 Frankfurt GmbH
Stake	100%
Seller	Sudarshan Germany Horizons GmbH
Buyer	Celanese Corporation / Celanese US Holdings LLC
Consideration	EUR 76.5 mn or INR ~8.45bn
Agreement signing date	31 August 2026
Closing	Subject to customary conditions

Source: Company, HSIE Research


VP4 is not a core pigment business. It manufactures chemical intermediates, including diketenes, operating largely as a tolling unit. Only a small part of its output is used internally by Sudarshan Germany Horizons**(Exhibit 5)**. Where VP4 becomes strategically interesting is in its relationship with Nutrinova, a producer of Ace-K sweetener and preservatives like sorbic acid and potassium sorbate **(Exhibit 6)**. VP4 is an important upstream supplier for Nutrinova, with Celanese acquiring and operating it temporarily before eventually transferring it into Nutrinova **(Exhibit 7)**.

Exhibit 5: VP4 manufacturing footprint




Source: Company, HSIE Research

Exhibit 6: Parties involved in the deal



Source: Company, HSIE Research

Exhibit 7: Deal rationale



Source: Company, HSIE Research

VP4 contributes roughly 2% to SCIL's consolidated revenues and 63% to the consolidated PAT as of FY26 **(Exhibit 8)**. To assess the impact of VP4's divestment, we have considered the FY26 numbers. We expect that they will receive the entire sales proceeds by the end of FY27, which will be used for debt repayment in FY28. Given the massive debt repayment, it will be able to save ~INR 379mn in interest costs post FY27 every year. Therefore, as per our estimates, there will be net positive impact of INR 9mn at the APAT level **(Exhibit 9)**.

Exhibit 8: VP4's contribution in SCIL's consolidated financials

All figures in INR mn, unless mentioned otherwise	FY26
Total Assets	**1,067**
Share Capital	2
Reserves and Surplus	616
Liabilities excl Equity	449
Sales	1,608
PAT	256
Total Liabilities	**1,067**
Net Assets	**618**
Net Assets as a % of consol net assets	**2%**
Revenue as a % of consol P/L	**2%**
PAT as a % of consol P/L	**63%**

Source: Company, HSIE Research


Exhibit 9: Potential impact on SCIL's consolidated financials post divestment

INR mn	FY25	FY26	FY27E	FY28E	FY29E	FY30E
Debt repaid using sale proceeds			-	8,460	-	100
Gross debt post repayment	**20,847**	**21,190**	**21,190**	**12,730**	**12,730**	**12,630**
Interest payment	483	1,649	1,483	1,187	891	888
Potential interest saving				**379**	**379**	**379**
Tax rate(%)	41	91	31	30	30	30
Pre div RPAT	**602**	**408**	**1,514**	**1,733**	**3,260**	**3,929**
PAT loss due to divestment			**256**	**256**	**256**	**256**
Addition to PAT	**-**	**-**	**-**	**265**	**265**	**265**
Adj RPAT	**602**	**408**	**1,258**	**1,742**	**3,270**	**3,938**

Source: Company, HSIE Research

The divestment is strategically important, especially when viewed in the broader context of Sudarshan's recent actions — the transformational Heubach acquisition, the selective Clariant aluminium dyes plant acquisition, and now the sale of VP4 Frankfurt GmbH. Though the transaction does not seem to be bottom-line accretive, we believe that SCIL is currently focusing on rationalizing the portfolio inherited through Heubach by selling the non-core assets, sharpening focus on strategic colour businesses by strategic bolt-on acquisitions, and potentially creating room for balance sheet deleveraging. We expect improvement in leverage ratios: **(i) Net debt to equity** is expected to improve from 0.14 in FY27 to 0.04 in FY30, **(ii) Net debt to EBITDA** is expected to improve from 0.85 in FY27 to 0.20 in FY30 and **(iii) interest coverage ratio** is expected to improve from 2.18 in FY27 to 13.06 in FY30 **(Exhibit 10)**.


Exhibit 10: Balance sheet deleveraging will improve leverage ratios



Source: Company, HSIE Research


SCIL plans to integrate all entities post Heubach acquisition under one entity and streamline supply chains to meet customer needs. It has been successful in rebuilding customer trust, as they have started ordering again, leading to restocking on Heubach products. The company is taking initiatives to improve customer service, capture value across manufacturing and procurement — inaugurated a Global Capability Center (GCC) and integrate all its processes and systems to one fully-integrated harmonized system. These initiatives will improve operational efficiency with benefits of integration expected to accrue FY27 onward. We expect +158/+184/+518bps improvement in EBITDA margin/PAT margin/RoE to 7.8/3.2/9.2 in FY30 from FY27 **(Exhibit 11)**. We expect revenue/EBITDA/APAT CAGR of 6/14/40% over FY27-FY30E **(Exhibit 12)**.

Exhibit 11: Initiatives undertaken will improve operational efficiency



Source: Company, HSIE Research

Exhibit 12: Revenue/EBITDA/APAT CAGR of 6/14/40% over FY27-FY30E



Source: Company, HSIE Research

Financials (Consolidated)

INCOME STATEMENT

INR mn	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY30E
Revenues	**25,388**	**33,456**	**97,872**	**1,08,782**	**1,14,652**	**1,21,472**	**1,28,678**
Growth %	***10.3***	***31.8***	***192.5***	***11.1***	***5.4***	***5.9***	***5.9***
Material expenses	14,154	17,737	49,718	55,686	66,123	68,087	71,359
Employee Cost	2,100	3,560	16,663	17,842	19,572	21,138	22,829
Other Expenses	5,970	8,348	25,592	28,488	21,962	23,080	24,449
EBITDA	**3,164**	**3,810**	**5,899**	**6,766**	**6,995**	**9,167**	**10,042**
EBIDTA Margin (%)	*12.5*	*11.4*	*6.0*	*6.2*	*6.1*	*7.5*	*7.8*
EBITDA Growth %	*50.2*	*20.4*	*54.8*	*14.7*	*3.4*	*31.0*	*9.5*
Depreciation	1,412	1,662	3,472	3,534	3,698	3,906	4,116
EBIT	**1,752**	**2,148**	**2,427**	**3,233**	**3,297**	**5,261**	**5,925**
Other Income (Including EO Items)	3,322	(702)	495	8,237	419	420	422
Interest	369	483	1,649	1,483	1,187	716	454
PBT	**4,705**	**963**	**1,273**	**9,986**	**2,528**	**4,965**	**5,894**
Tax	1,131	390	1,158	3,104	759	1,490	1,768
Share of Profits from JV/Associates	0	0	293	0	0	0	0
RPAT	**3,574**	**602**	**408**	**6,882**	**1,779**	**3,485**	**4,135**
EO (Loss) / Profit (Net Of Tax)	2,459	(834)	(78)	5,389	-	-	-
APAT	**2,716**	**1,436**	**486**	**1,494**	**1,779**	**3,485**	**4,135**
Minority Interest	-	-	-	-	-	-	-
Consolidated APAT	**2,716**	**1,436**	**486**	**1,494**	**1,779**	**3,485**	**4,135**
Consolidated APAT Growth (%)	*506.7*	*(47.1)*	*(66.2)*	*207.4*	*19.1*	*95.9*	*18.7*
AEPS	**34.2**	**18.1**	**6.1**	**18.8**	**22.4**	**43.8**	**52.0**
AEPS Growth %	*506.7*	*(47.1)*	*(66.2)*	*207.4*	*19.1*	*95.9*	*18.7*

Source: Company, HSIE Research

BALANCE SHEET

INR mn	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY30E
SOURCES OF FUNDS							
Share Capital	138	157	157	157	157	157	157
Reserves And Surplus	11,352	33,767	34,345	40,630	41,697	43,788	46,269
Total Equity	**11,490**	**33,924**	**34,502**	**40,787**	**41,854**	**43,945**	**46,426**
Minority Interest	-	5,982	4,038	4,038	4,038	4,038	4,038
Long-term Debt	1,933	16,319	16,479	16,479	8,019	3,019	519
Short-term Debt	2,476	4,528	4,711	4,711	4,711	4,711	4,711
Total Debt	**4,409**	**20,847**	**21,190**	**21,190**	**12,730**	**7,730**	**5,230**
Deferred Tax Liability	911	2,475	2,951	3,040	3,131	3,225	3,321
Long-term Provision and others	591	9,096	10,288	10,494	10,704	10,918	11,136
TOTAL SOURCES OF FUNDS	**17,401**	**72,324**	**72,969**	**79,548**	**72,457**	**69,856**	**70,152**
APPLICATION OF FUNDS							
Net Block	11,016	27,737	29,872	27,868	26,718	25,410	23,894
Capital WIP	145	1,213	1,443	1,347	1,298	1,299	1,300
LT Loans and Advances	432	2,462	3,840	3,917	3,995	4,075	4,157
Total Non-current Investments	24	2,164	2,434	2,434	2,434	2,434	2,434
Total Non-current assets	**11,617**	**33,576**	**37,589**	**35,565**	**34,445**	**33,219**	**31,784**
Inventories	4,376	25,018	24,436	27,160	28,626	30,328	32,127
Debtors	5,853	12,250	16,790	18,662	19,669	20,839	22,075
Cash & Equivalents	559	15,112	10,749	15,421	6,937	2,876	3,189
Other Current Assets	1,145	10,973	7,669	7,822	7,979	8,138	8,301
Total Current Assets	**11,933**	**63,353**	**59,644**	**69,065**	**63,210**	**62,182**	**65,692**
Creditors	5,120	13,937	15,340	17,050	17,970	19,039	20,168
Other Current Liabilities	1,028	10,667	8,924	8,032	7,228	6,506	7,156
Total Current Liabilities	**6,149**	**24,604**	**24,264**	**25,082**	**25,198**	**25,545**	**27,325**
Net Current Assets	**5,784**	**38,748**	**35,380**	**43,983**	**38,012**	**36,637**	**38,368**
TOTAL APPLICATION OF FUNDS	**17,401**	**72,324**	**72,969**	**79,548**	**72,457**	**69,856**	**70,152**

Source: Company, HSIE Research

CASH FLOW STATEMENT

INR mn	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY30E
Reported PBT	4,705	963	1,566	9,986	2,528	4,965	5,894
Non-operating & EO items	(3,322)	702	(495)	(8,237)	(419)	(420)	(422)
Interest expenses	369	483	1,649	1,483	1,187	716	454
Depreciation	1,412	1,662	3,472	3,534	3,698	3,906	4,116
Working Capital Change	(121)	(18,411)	(995)	(3,931)	(2,512)	(2,686)	(1,418)
Tax Paid	(936)	1,174	(682)	(3,016)	(667)	(1,396)	(1,671)
OPERATING CASH FLOW (a)	**2,107**	**(13,427)**	**4,515**	**(180)**	**3,816**	**5,085**	**6,952**
Capex	(866)	(19,451)	(5,837)	(1,433)	(2,500)	(2,600)	(2,600)
Free cash flow (FCF)	1,241	(32,878)	(1,322)	(1,613)	1,316	2,485	4,352
Investments	(4)	(2,140)	(270)	-	-	-	-
Non-operating Income	3,322	(702)	495	8,237	419	420	422
Others	112	(2,030)	(1,378)	(77)	(78)	(80)	(82)
Divestment of subsidiary	-	-	-	-	-	-	-
INVESTING CASH FLOW (b)	**2,564**	**(24,323)**	**(6,990)**	**6,727**	**(2,160)**	**(2,260)**	**(2,259)**
Debt Issuance/(Repaid)	(3,766)	16,437	343	-	(8,460)	(5,000)	(2,500)
Interest Expenses	(369)	(483)	(1,649)	(1,483)	(1,187)	(716)	(454)
FCFE	(2,894)	(16,924)	(2,627)	(3,097)	(8,331)	(3,231)	1,398
Share Capital Issuance	-	19	(0)	-	-	-	-
Dividend	-	-	-	-	-	-	-
Others	(272)	36,301	(582)	(392)	(502)	(1,180)	(1,436)
FINANCING CASH FLOW (c)	**(4,406)**	**52,274**	**(1,888)**	**(1,875)**	**(10,149)**	**(6,896)**	**(4,389)**
NET CASH FLOW (a+b+c)	**265**	**14,524**	**(4,363)**	**4,672**	**(8,493)**	**(4,070)**	**303**
EO Items, Others							
Closing Cash & Equivalents	**559**	**15,083**	**10,749**	**15,421**	**6,928**	**2,867**	**3,180**


Source: Company, HSIE Research

KEY RATIOS

	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY30E
PROFITABILITY %							
Gross Margin	44	47	49	49	42	44	45
EBITDA Margin	12.5	11.4	6.0	6.2	6.1	7.5	7.8
EBIT Margin	6.9	6.4	2.5	3.0	2.9	4.3	4.6
APAT Margin	10.7	4.3	0.5	1.4	1.6	2.9	3.2
RoE	27.5	6.3	1.4	4.0	4.3	8.1	9.2
RoIC	4.0	5.1	0.5	(2.5)	3.8	5.9	6.6
RoCE	17.1	3.8	0.9	3.3	3.4	5.6	6.4
EFFICIENCY							
Tax Rate %	24.0	40.5	91.0	31.1	30.0	30.0	30.0
Fixed Asset Turnover (x)	1.5	1.3	2.5	2.5	2.5	2.5	2.5
Inventory (days)	63	273	91	91	91	91	91
Debtors (days)	84	134	63	63	63	63	63
Other Current Assets (days)	16	120	29	26	25	24	24
Payables (days)	74	152	57	57	57	57	57
Other Current Liab & Provns (days)	15	116	33	27	23	20	20
Cash Conversion Cycle (days)	75	258	92	96	99	101	100
Net Debt/EBITDA (x)	1.22	1.51	1.77	0.85	0.83	0.53	0.20
Net D/E	0.34	0.17	0.30	0.14	0.14	0.11	0.04
Interest Coverage	4.75	4.45	1.47	2.18	2.78	7.35	13.06
PER SHARE DATA (INR)							
EPS	34.2	18.1	6.1	18.8	22.4	43.8	52.0
CEPS	51.9	39.0	49.8	63.2	68.9	93.0	103.8
Dividend	13.7	-	2.4	7.5	9.0	17.5	20.8
Book Value	144.5	426.7	434.0	513.0	526.5	552.8	584.0
VALUATION							
P/E (x)	35.7	67.5	199.4	64.9	54.5	27.8	23.4
P/BV (x)	8.4	2.9	2.8	2.4	2.3	2.2	2.1
EV/EBITDA (x)	31.8	26.9	18.2	15.2	14.7	11.1	9.9
OCF/EV (%)	2.1	(13.1)	4.2	(0.2)	3.7	5.0	7.0
FCFF/EV (%)	1.2	(32.0)	(1.2)	(1.6)	1.3	2.4	4.4
FCFE/M Cap (%)	(3.0)	(17.5)	(2.7)	(3.2)	(8.6)	(3.3)	1.4
Dividend Yield (%)	1.1	-	0.2	0.6	0.7	1.4	1.7

Source: Company, HSIE Research

Price history



Rating Criteria

BUY: >+15% return potential
ADD: +5% to +15% return potential
REDUCE: -10% to +5% return potential
SELL: >10% Downside return potential

Disclosure:

We, **Nilesh Ghuge, MMS, Aditya Iyer, PGDM & Priya Gupta, MSc** authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in the stock - NO

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. "This report may have been refined using AI tools to enhance clarity and readability."

Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg(East), Mumbai 400 042 Tel.: +91-22-30753400 Fax: +91-22-30753435 www.hdfcsec.com

Compliance Officer: Murli V Karkera, Contact: +91 022-69151436, Email: complianceofficer@hdfcsec.com, For any complaints / grievance: services@hdfcsec.com

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475. BSE Enlistment Number: 5159; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

SEBI Registration & Disclaimer https://www.hdfcsec.com/article/disclaimer-1795.

HDFC Securities
Institutional Equities
Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,
Senapati Bapat Marg, Lower Parel, Mumbai - 400 013
Board: +91-22-6171-7330 www.hdfcsec.com